, Volume 8, Issue 1, pp 33-34,
Open Access This content is freely available online to anyone, anywhere at any time.

Biomarkers in Osteoarthritis

This is an excerpt from the content

Introduction

The current gold standard for assessing joint damage in osteoarthritis (OA) remains the plane radiograph. This technique is relatively insensitive and only provides a historical view of the skeletal damage that has already occurred. It does not allow for the early detection of pathological changes in joint tissues. MRI and biochemical biomarkers are likely to be more sensitive than radiology in detecting joint changes that occur in OA.

Developing Biomarkers for the Study of OA

Biomarkers are defined as objective indicators of normal biologic processes, pathogenic processes, or pharmacologic responses to therapeutic interventions. Biomarkers have the potential to decrease the length and cost of clinical trials. Thus, biomarkers that can measure and predict the full spectrum of OA disease progression and outcomes are needed, but few such biomarkers have been validated for this purpose. Many laboratories worldwide are working on the development of these biomarkers. To coordinate